Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 10:10:1712.
doi: 10.3389/fonc.2020.01712. eCollection 2020.

Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study

Xuejiao Yin  1 , Lei Chen  1 , Fengjuan Fan  1 , Han Yan  1 , Yuyang Zhang  1 , Zhenli Huang  1 , Chunyan Sun  1   2 , Yu Hu  1   2
Affiliations

Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study

Xuejiao Yin et al. Front Oncol. .

Erratum in

Abstract

Background: The incidence of Waldenström macroglobulinemia (WM) has increased in certain groups over several decades in the United States. It is unclear whether the increasing incidence is associated with mortality trends. Methods: The incidence and incidence-based mortality (IBM) rates were obtained from the Surveillance, Epidemiology, and End Results (SEER) database (1980-2016) with SEER*Stat software. The secular trends stratified by demographic characteristics were analyzed by joinpoint regression. Results: The incidence of WM showed an initial rapid increase from 1980 to 1993 {annual percentage change (APC), 14.1% [95% confidence interval (CI), 10 to 18.4%]}, whereas it began to stabilize from 1993 to 2016 [APC, 0.5% (95% CI, -0.3 to 1.3%)]. The WM IBM trend followed a similar pattern, with a decrease occurring around 1994. The trends in the incidence and mortality significantly differed according to geographic location, race, age, sex, primary site of involvement and subtype, which could help in further investigations into the specific etiology. Moreover, a dramatic increase in the 5-year survival rate from the 1980s to 2010s was observed (47.84 vs. 69.41%). Conclusions: Although both the incidence and IBM of WM continued to increase during the study period, a reduction in the rate of increase occurred around 1993. We believe that further advances in healthcare delivery and research can ensure a low mortality rate. Future studies can use the findings of this paper to monitor the results of WM therapy.

Keywords: and end results (SEER); epidemiology; incidence; incidence-based mortality; surveillance; survival; waldenström macroglobulinemia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The overall trends in the incidence of Waldenström macroglobulinemia.
Figure 2
Figure 2
The overall trends in the incidence-based mortality of Waldenström macroglobulinemia.
Figure 3
Figure 3
Trends in the annual incidence of Waldenström macroglobulinemia in patients stratified according to sex.
Figure 4
Figure 4
Trends in the annual incidence-based mortality of Waldenström macroglobulinemia in patients stratified according to sex.
Figure 5
Figure 5
Trends in the annual incidence of Waldenström macroglobulinemia in patients stratified according to age.
Figure 6
Figure 6
Trends in the annual incidence-based mortality of Waldenström macroglobulinemia in patients stratified according to age.
Figure 7
Figure 7
Trends in the annual incidence of Waldenström macroglobulinemia in patients stratified according to race.
Figure 8
Figure 8
Trends in the annual incidence-based mortality of Waldenström macroglobulinemia in patients stratified according to race.
Figure 9
Figure 9
Kaplan–Meier analysis for the overall survival of Waldenström macroglobulinemia. The graph shows increasing survival from the 1980s to 2010s.
See this image and copyright information in PMC

References

    1. Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. (2010) 102:83–7. Available online at: https://www.crossref.org/guestquery/ - PubMed
    1. Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer. (2012) 118:3793–800. 10.1002/cncr.26627 - DOI - PubMed
    1. Castillo JJ, Olszewski AJ, Cronin AM, Hunter ZR, Treon SP. Survival trends in Waldenstrom macroglobulinemia: an analysis of the surveillance, epidemiology and end results database. Blood. (2014) 123:3999–4000. 10.1182/blood-2014-05-574871 - DOI - PubMed
    1. Kastritis E, Kyrtsonis MC, Hatjiharissi E, Symeonidis A, Michalis E, Repoussis P, et al. No significant improvement in the outcome of patients with Waldenstrom's macroglobulinemia treated over the last 25 years. Am J Hematol. (2011) 86:479–83. 10.1002/ajh.22027 - DOI - PubMed
    1. Kristinsson SY, Eloranta S, Dickman PW, Andersson TM, Turesson I, Landgren O, et al. Patterns of survival in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. Am J Hematol. (2013) 88:60–5. 10.1002/ajh.23351 - DOI - PMC - PubMed

LinkOut - more resources